Amiodarone is a class III antiarrhythmic drug, mainly acting on potassium channels, but it combines the effects of class I sodium channel blockade, class II beta receptor blockade, and class IV calcium channel blockade, and is the most widely used antiarrhythmic drug in clinical practice, without increasing the rate of death from organic heart disease. It can be used for the conversion of atrial fibrillation and control of atrial fibrillation ventricular rate, and oral amiodarone can also be used for pre-excitation combined with atrial fibrillation. Contraindications: severe sinus node insufficiency (severe sinus bradycardia, syncope), degree II/III AVB, iodine hypersensitivity, cardiogenic shock, abnormal thyroid function, severe pulmonary disease. Intravenous administration: 150mg pushing >10min, 1mg/min IV pumping for 6h then reduced to 0.5mg/min. Oral administration: 200mg tid 7d→200mg bid 7d→200mg qd maintenance. Short-term adverse reactions: vasodilation, hypotension, negative inotropic effects, prolonged QT interval, phlebitis, elevated INR values, abnormal liver function. Long-term adverse reactions: bradycardia, AV block, visual impairment, skin damage, interstitial pneumonia, GI symptoms, elevated liver enzymes, hyper/hypothyroidism, ataxia, sensory abnormalities, peripheral neuropathy.